NCT05391178Completed
Improving Disease Severity
Improving Disease Severity in Alopecia Areata, Polymorphous Light Eruption, and Psoriasis Patients With Lumiton Technology
Source: ClinicalTrials.gov · Last updated 6 May 2026
Brief summary (registry, in English)
Phototherapy, including ultraviolet B (UVB) and ultraviolet A (UVA) light, has been used to treat a number of dermatologic conditions. Psoriasis is one of the most common conditions treated with phototherapy, in which phototherapy is often indicated for extensive disease with contraindications for other systemic treatments. The mechanism of action of phototherapy for the treatment of psoriasis is not completely understood; however, it is known that UVB light induces apoptosis of pathogenic T cells and keratinocytes, which may reduce the overactive immune response and epidermal hyperproliferation. Phototherapy has shown some efficacy for other diseases, such as alopecia areata (AA) and polymorphous light eruption (PMLE). However, phototherapy is not always an accessible treatment option for patients due to cost or lack of time.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 18 (actual)
- First submitted
- 20 May 2022
- Start date
- 9 Aug 2022
- Primary completion date
- 15 May 2024
- Lead sponsor
- Wake Forest University Health Sciences
- Diseases
- Psoriasis
- NCT number
- NCT05391178
What you commit to
- Study type: Interventional
- Participants enrolled: 18
- From 9 Aug 2022 to the primary completion date, 15 May 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participants with concurrent medical conditions that are at risk of confounding the study outcomes
- Participants currently using concomitant phototherapy
Age
- Participants less than the age of 18
Other
- Participants who do not live in the US
- Participants who are not diagnosed with mild to severe AA, PMLE, or psoriasis
- Participants without a sufficient command of the English language
Who the study is looking for
- Adult participants ≥18 years of age
- Participants who live in the US,
- Participants who are diagnosed with mild-to-severe AA, PMLE, or psoriasis
- Participants have sufficient command of the English language
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Wake Forest University Health Sciences, Dermatology Coordinator of this site? Confirm its status | Winston-Salem | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.